Product Code: A06278
Title:
Anti-Viral Therapies Market by Type (Generic Drugs and Branded Drugs), Application (HIV, Hepatitis, Herpes Virus, Influenza, and Other Applications), and Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others): Global Opportunity Analysis and Industry Forecast, 2019-2026.
The global anti-viral therapies market was valued at $38,316.5 million in 2018, and is projected to reach $46,213.4 million by 2026 registering a CAGR of 2.4% from 2019 to 2026. Antiviral drugs belong to the class of medicines, which are used for treating viral infections, such as HIV, herpes, hepatitis, and influenza. These drugs are generally administered in the form of vaccines. In addition, most of these drugs are used for specific viral infections, while a few (broad-spectrum antiviral drugs) are effective against a wide range of viruses.
The global antiviral therapies market is majorly driven by increase in the incidence rate of viral infections. In addition, rise in R&D activities and development of newer & advanced formulations, such as vaccines and combination therapy along with pipeline products, are expected to fuel the market growth. However, high cost involved in the treatment and rise in demand for alternative medicines such as naturopathy and homeopathy are likely to restrain the market growth. On the contrary, development and approvals of combination therapies and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are anticipated to provide numerous opportunities for the market growth during the forecast period.
The global antiviral therapies market is segmented on the basis of application, type, mechanism of action, and region. Based on application, the market is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. On the basis of type, it is classified into generic drugs and branded drugs. By mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global clinical nutrition market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
By Application
- HIV
- Hepatitis
- Herpes Virus
- Influenza
- Other Applications
By Type
- Generic Drugs
- Branded Drugs
By Mechanism of Action
- Nucleotide Polymerase Inhibitor
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- Spain
- Italy
- UK
- Rest of Europe
- Asia-Pacific
- Japan
- India
- China
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- KEY MARKET PLAYERS
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, GlaxoSmithKline
- Bristol-Myers-Squibb
- Abbott Laboratories
- AstraZeneca plc
- AbbVie Inc.
- Aurobindo Pharma Limited
- Johnson & Johnson
- Merck & Co., Inc
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key benefits for stakeholders
- 1.3.Key market segments
- 1.4.Research methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.2.2.Top winning strategies
- 3.3.Market dynamics
- 3.3.1.Drivers
- 3.3.1.1.Surge in global burden of viral infection
- 3.3.1.2.Stronger pipeline of anti-viral drugs
- 3.3.2.Restraints
- 3.3.2.1.Higher cost of treatment
- 3.3.3.Opportunities
- 3.3.3.1.Increase in number of product approvals for combination therapy
CHAPTER 4:ANTI-VIRAL THERAPIES MARKET, BY APPLICATION
- 4.1.Overview
- 4.1.1.Market size and forecast
- 4.2.HIV
- 4.2.1.Key market trends, growth factors, and opportunities
- 4.2.2.Market size and forecast, by region
- 4.2.3.Market analysis, by country
- 4.3.Hepatitis
- 4.3.1.Key market trends, growth factors, and opportunities
- 4.3.2.Market size and forecast, by region
- 4.3.3.Market analysis, by country
- 4.4.Herpes virus
- 4.4.1.Key market trends, growth factors, and opportunities
- 4.4.2.Market size and forecast, by region
- 4.4.3.Market analysis, by country
- 4.5.Influenza
- 4.5.1.Key market trends, growth factors, and opportunities
- 4.5.2.Market size and forecast, by region
- 4.5.3.Market analysis, by country
- 4.6.Other Applications
- 4.6.1.Key market trends, growth factors, and opportunities
- 4.6.2.Market size and forecast, by region
- 4.6.3.Market analysis, by country
CHAPTER 5:ANTI-VIRAL THERAPIES MARKET, BY TYPE
- 5.1.Overview
- 5.1.1.Market size and forecast
- 5.2.Generic drugs
- 5.2.1.Market size and forecast, by region
- 5.2.2.Market analysis, by country
- 5.3.Branded drugs
- 5.3.1.Market size and forecast, by region
- 5.3.2.Market analysis, by country
CHAPTER 6:ANTI-VIRAL THERAPIES MARKET, BY MECHANISM OF ACTION
- 6.1.Overview
- 6.1.1.Market size and forecast
- 6.2.Nucleotide polymerase inhibitor
- 6.2.1.Market size and forecast, by region
- 6.2.2.Market analysis, by country
- 6.3.Reverse transcriptase inhibitors
- 6.3.1.Market size and forecast, by region
- 6.3.2.Market analysis, by country
- 6.4.Protease inhibitors
- 6.4.1.Market size and forecast, by region
- 6.4.2.Market analysis, by country
- 6.5.Others
- 6.5.1.Market size and forecast, by region
- 6.5.2.Market analysis, by country
CHAPTER 7:GLOBAL ANTI-VIRAL THERAPIES MARKET, BY REGION
- 7.1.Overview
- 7.1.1.Market size and forecast
- 7.2.North America
- 7.2.1.Key market trends and opportunities
- 7.2.2.Market size and forecast, by type
- 7.2.3.Market size and forecast, by mechanism of action
- 7.2.4.Market size and forecast, by application
- 7.2.5.Market size and forecast, by country
- 7.2.5.1.U.S. market size and forecast, by type
- 7.2.5.2.U.S. Market size and forecast, by mechanism of action
- 7.2.5.3.U.S. market size and forecast, by application
- 7.2.5.4.Canada market size and forecast, by type
- 7.2.5.5.Canada Market size and forecast, by mechanism of action
- 7.2.5.6.Canada market size and forecast, by application
- 7.2.5.7.Mexico market size and forecast, by type
- 7.2.5.8.Mexico Market size and forecast, by mechanism of action
- 7.2.5.9.Mexico market size and forecast, by application
- 7.3.Europe
- 7.3.1.Key market trends and opportunities
- 7.3.2.Market size and forecast, by type
- 7.3.3.Market size and forecast, by mechanism of action
- 7.3.4.Market size and forecast, by application
- 7.3.5.Market size and forecast, by country
- 7.3.5.1.Germany market size and forecast, by type
- 7.3.5.2.Germany Market size and forecast, by mechanism of action
- 7.3.5.3.Germany market size and forecast, by application
- 7.3.5.4.France market size and forecast, by type
- 7.3.5.5.France Market size and forecast, by mechanism of action
- 7.3.5.6.France market size and forecast, by application
- 7.3.5.7.UK market size and forecast, by type
- 7.3.5.8.UK Market size and forecast, by mechanism of action
- 7.3.5.9.UK market size and forecast, by application
- 7.3.5.10.Italy market size and forecast, by type
- 7.3.5.11.Italy Market size and forecast, by mechanism of action
- 7.3.5.12.Italy market size and forecast, by application
- 7.3.5.13.Spain market size and forecast, by type
- 7.3.5.14.Spain Market size and forecast, by mechanism of action
- 7.3.5.15.Spain market size and forecast, by application
- 7.3.5.16.Rest of Europe market size and forecast, by type
- 7.3.5.17.Rest of Europe Market size and forecast, by mechanism of action
- 7.3.5.18.Rest of Europe market size and forecast, by application
- 7.4.Asia-Pacific
- 7.4.1.Key market trends and opportunities
- 7.4.2.Market size and forecast, by type
- 7.4.3.Market size and forecast, by mechanism of action
- 7.4.4.Market size and forecast, by application
- 7.4.5.Market size and forecast, by country
- 7.4.5.1.Japan market size and forecast, by type
- 7.4.5.2.Japan Market size and forecast, by mechanism of action
- 7.4.5.3.Japan market size and forecast, by application
- 7.4.5.4.China market size and forecast, by type
- 7.4.5.5.China Market size and forecast, by mechanism of action
- 7.4.5.6.China market size and forecast, by application
- 7.4.5.7.India market size and forecast, by type
- 7.4.5.8.India Market size and forecast, by mechanism of action
- 7.4.5.9.India market size and forecast, by application
- 7.4.5.10.Australia market size and forecast, by type
- 7.4.5.11.Australia Market size and forecast, by mechanism of action
- 7.4.5.12.Australia market size and forecast, by application
- 7.4.5.13.South Korea market size and forecast, by type
- 7.4.5.14.South Korea Market size and forecast, by mechanism of action
- 7.4.5.15.South Korea market size and forecast, by application
- 7.4.5.16.Rest of Asia-Pacific market size and forecast, by type
- 7.4.5.17.Rest of Asia-Pacific Market size and forecast, by mechanism of action
- 7.4.5.18.Rest of Asia-Pacific market size and forecast, by application
- 7.5.LAMEA
- 7.5.1.Key market trends and opportunities
- 7.5.2.Market size and forecast, by type
- 7.5.3.Market size and forecast, by mechanism of action
- 7.5.4.Market size and forecast, by application
- 7.5.5.Market size and forecast, by country
- 7.5.5.1.Brazil market size and forecast, by type
- 7.5.5.2.Brazil Market size and forecast, by mechanism of action
- 7.5.5.3.Brazil market size and forecast, by application
- 7.5.5.4.Saudi market size and forecast, by type
- 7.5.5.5.Saudi Market size and forecast, by mechanism of action
- 7.5.5.6.Saudi market size and forecast, by application
- 7.5.5.7.South Africa market size and forecast, by type
- 7.5.5.8.South Africa Market size and forecast, by mechanism of action
- 7.5.5.9.South Africa market size and forecast, by application
- 7.5.5.10.Rest of LAMEA market size and forecast, by type
- 7.5.5.11.Rest of LAMEA Market size and forecast, by mechanism of action
- 7.5.5.12.Rest of LAMEA market size and forecast, by application
CHAPTER 8:COMPANY PROFILES
- 8.1.Abbott Laboratories
- 8.1.1.Company overview
- 8.1.2.Company snapshot
- 8.1.3.Operating business segments
- 8.1.4.Product portfolio
- 8.1.5.Business performance
- 8.2.AbbVie Inc.
- 8.2.1.Company overview
- 8.2.2.Company snapshot
- 8.2.3.Operating business segments
- 8.2.4.Business performance
- 8.2.5.Key strategic moves and developments
- 8.3.Bristol Myers Squibb Company
- 8.3.1.Company overview
- 8.3.2.Company snapshot
- 8.3.3.Operating business segments
- 8.3.4.Product portfolio
- 8.3.5.Business performance
- 8.4.F. Hoffmann-La Roche Ltd.
- 8.4.1.Company overview
- 8.4.2.Company snapshot
- 8.4.3.Operating business segments
- 8.4.4.Product portfolio
- 8.4.5.Business performance
- 8.4.6.Key strategic moves and developments
- 8.5.Johnson & Johnson
- 8.5.1.Company overview
- 8.5.2.Company snapshot
- 8.5.3.Operating business segments
- 8.5.4.Business performance
- 8.6.Merck & Co., Inc.
- 8.6.1.Company overview
- 8.6.2.Company snapshot
- 8.6.3.Operating business segments
- 8.6.4.Business performance
- 8.6.5.Key strategic moves and developments
- 8.7.GILEAD SCIENCES, INC.
- 8.7.1.Company overview
- 8.7.2.Company snapshot
- 8.7.3.Operating business segments
- 8.7.4.Product portfolio
- 8.7.5.Business performance
- 8.7.6.Key strategic moves and developments
- 8.8.GlaxoSmithKline Plc.
- 8.8.1.Company overview
- 8.8.2.Company snapshot
- 8.8.3.Operating business segments
- 8.8.4.Product portfolio
- 8.8.5.Business performance
- 8.8.6.Key strategic moves and developments
- 8.9.AstraZeneca PLC
- 8.9.1.Company overview
- 8.9.2.Company snapshot
- 8.9.3.Operating business segments
- 8.9.4.Product portfolio
- 8.9.5.Business performance
- 8.9.6.Key strategic moves and developments
- 8.10.Aurobindo Pharma Limited
- 8.10.1.Company overview
- 8.10.2.Company snapshot
- 8.10.3.Operating business segments
- 8.10.4.Product portfolio
- 8.10.5.Business performance
比較リスト
